Clinical Research Of Urinary Kallikrein In Patients With Acute Cerebral Infarction

Objective:To investigate the changes of vascular endothelial growth factor (VEGF), high sensitivity C-reactive protein (hs-CRP) and S-100B protein (S100B) in patients with acute cerebral infarction and its clinical significance, to further explore protective effect and security of Urinary Kallikrein and its possible mechanism.Methods:56patients with acute cerebral infarction within were divided into routine treatment group and Urinary Kallikrein treatment group.The two groups received the same routine treatment, including anti-platelet aggregation, improving cerebral circulation, symptomatic treatment and nerves convalescent care. Patients in the Urinary Kallikrein treatment group received Urinary Kallikrein0.15PNAU/d for14days on the routine treatment. To compare the National Institutes of Health Stroke Scale (NIHSS) score before and after admission in patients with ACI, in both routine group and Urinary Kallikrein group, to evaluate the clinical efficacy. Before and after treatment, the serum levels of hs-CRP, VEGF, S100B and NSE was measured through enzyme immunoassay. The patients were evaluated by the biochemical indicator before and after14days therapy. SPSS17.0version was used for statistical analysis and P<0.05was reared as statistical significance.Results:(1)There was no significant difference between routine treatment group and Urinary Kallikrein group in the NIHSS scores of neurological deficits before treatment(P>0.05); the scores of the two groups significantly decreased on the14th day after treatment(P<0.05),but Urinary Kallikrein group were much less than routine group(P<0.05).(2)There was no significant difference between routine treatment group and Urinary Kallikrein group in the serum levels of hs-CRP,S100B content before treatment(P>0.05); the levels of serum hs-CRP,S100B content significantly decreased on the14th day after treatment in two groups(P<0.05),however, the levels of serum hs-CRP,S100B were significantly lower in Urinary Kallikrein group than in routine treatment group(P<0.05).(3)There was no significant difference between routine treatment group and Urinary Kallikrein group in the serum levels of VEGF before treatment(P>0.05); the levels of serum VEGF significantly increased on the14th day after treatment in two groups(P<0.05),however,the levels of serum VEGF was significantly higher in Urinary Kallikrein group than in routine treatment group(P<0.05).(4)In the Urinary Kallikrein group,there was no significantly different between before and after14days therapy in biochemical indicator(P>0.05).Conclusion:Urinary Kallikrein can improve the neurological deficit, reduce the serum levels of hs-CRP, S100B content, and increase VEGF content in patients with acute cerebral infarction, protect ischemic brain tissue. The protective neural functions mechanisms may be derived from promoting local angiogenesis after cerebral ischemia, reducing the extent of inflammatory injure in the course of cerebral ischemia, improving clinical neurological deficits, and protect impaired neuron. It is safe and effective to use Urinary Kallikrein intreatment of acute cerebral infarction.